199 related articles for article (PubMed ID: 16155027)
1. Current treatment approaches for mantle-cell lymphoma.
Witzig TE
J Clin Oncol; 2005 Sep; 23(26):6409-14. PubMed ID: 16155027
[TBL] [Abstract][Full Text] [Related]
2. The clinical features, therapeutic responses, and prognosis of the patients with mantle cell lymphoma.
Ying ZT; Zheng W; Wang XP; Xie Y; Tu MF; Lin NJ; Ping LY; Liu WP; Deng LJ; Zhang C; Zhu J; Song YQ
Chin J Cancer; 2012 Jul; 31(7):348-53. PubMed ID: 22704490
[TBL] [Abstract][Full Text] [Related]
3. Optimized adoptive T-cell therapy for the treatment of residual mantle cell lymphoma.
Munger CM; Hegde GV; Weisenburger DD; Vose JM; Joshi SS
Cancer Immunol Immunother; 2012 Oct; 61(10):1819-32. PubMed ID: 22441656
[TBL] [Abstract][Full Text] [Related]
4. Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches.
Shah BD; Martin P; Sotomayor EM
Cancer Control; 2012 Jul; 19(3):227-35. PubMed ID: 22710898
[TBL] [Abstract][Full Text] [Related]
5. The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?
Dreyling M; Ferrero S;
Haematologica; 2016 Feb; 101(2):104-14. PubMed ID: 26830211
[TBL] [Abstract][Full Text] [Related]
6. Management of Mantle Cell Lymphoma in the Era of Novel Oral Agents.
Buege MJ; Kumar A; Dixon BN; Tang LA; Pak T; Orozco J; Peterson TJ; Maples KT
Ann Pharmacother; 2020 Sep; 54(9):879-898. PubMed ID: 32079411
[No Abstract] [Full Text] [Related]
7. Adverse events, resource use, and economic burden associated with mantle cell lymphoma: a real-world assessment of privately insured patients in the United States.
Goyal RK; Nagar SP; Kabadi SM; Kaye JA; Seal B; Mato AR
Leuk Lymphoma; 2019 Apr; 60(4):955-963. PubMed ID: 30277099
[TBL] [Abstract][Full Text] [Related]
8. The effectiveness and harms of bortezomib in combination with chemotherapy for mantle cell lymphoma: A protocol for systematic review and meta-analysis.
Wang X; Li W; Wang X; Liu X; Feng C; Li Y; Li J
Medicine (Baltimore); 2020 Jul; 99(28):e20961. PubMed ID: 32664099
[TBL] [Abstract][Full Text] [Related]
9. Effects of the Proteasome Inhibitor Bortezomib in Combination with Chemotherapy for the Treatment of Mantle Cell Lymphoma: A Meta-analysis.
Li SJ; Hao J; Mao Y; Si YL
Turk J Haematol; 2020 Feb; 37(1):13-19. PubMed ID: 31464119
[TBL] [Abstract][Full Text] [Related]
10. SOX11 augments BCR signaling to drive MCL-like tumor development.
Kuo PY; Jatiani SS; Rahman AH; Edwards D; Jiang Z; Ahr K; Perumal D; Leshchenko VV; Brody J; Shaknovich R; Ye BH; Parekh S
Blood; 2018 May; 131(20):2247-2255. PubMed ID: 29615403
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological Features of Ocular Adnexal Mantle-Cell Lymphoma in an International Multicenter Cohort.
Knudsen MKH; Rasmussen PK; Coupland SE; Esmaeli B; Finger PT; Graue GF; Grossniklaus HE; Khong JJ; McKelvie PA; Mulay K; Ralfkiaer E; Sjö LD; Vemuganti GK; Thuro BA; Curtin J; Heegaard S
JAMA Ophthalmol; 2017 Dec; 135(12):1367-1374. PubMed ID: 29121219
[TBL] [Abstract][Full Text] [Related]
12. Indian Council of Medical Research Consensus Document for the Management of Non-Hodgkin's Lymphoma (High Grade).
Doval DC; Bhurani D; Nair R; Gujral S; Malhotra P; Ramanan G; Mohan R; Biswas G; Dattatreya S; Agarwal S; Pendharkar D; Julka PK; Advani SH; Dhaliwal RS; Tayal J; Sinha R; Kaur T; Rath GK
Indian J Med Paediatr Oncol; 2017; 38(1):51-58. PubMed ID: 28469337
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes of high dose treatment and autologous stem cell transplantation in follicular and mantle cell lymphomas - a single centre experience.
Boltezar L; Pintaric K; Pretnar J; Pohar Perme M; Novakovic BJ
Radiol Oncol; 2017 Mar; 51(1):81-87. PubMed ID: 28265236
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma.
van Keep M; Gairy K; Seshagiri D; Thilakarathne P; Lee D
BMC Cancer; 2016 Aug; 16(1):598. PubMed ID: 27488675
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of both abbreviated hyper-CVAD induction followed by autologous hematopoietic cell transplantation and conventional chemotherapy for mantle cell lymphoma: a 10-year single-centre experience with literature review.
Alwasaidi TA; Hamadah A; Altouri S; Tay J; McDiarmid S; Faught C; Allan D; Huebsch L; Bredeson C; Bence-Bruckler I
Cancer Med; 2015 Dec; 4(12):1817-27. PubMed ID: 26432256
[TBL] [Abstract][Full Text] [Related]
16. Direct and immune-mediated cytotoxicity of interleukin-21 contributes to antitumor effects in mantle cell lymphoma.
Bhatt S; Matthews J; Parvin S; Sarosiek KA; Zhao D; Jiang X; Isik E; Letai A; Lossos IS
Blood; 2015 Sep; 126(13):1555-64. PubMed ID: 26194763
[TBL] [Abstract][Full Text] [Related]
17. Mantle cell lymphoma of the oral cavity with multiple foci: a case report and review of the literature.
Rajkumar K; Rao R; Chawla N; Bandyopadhyay TK; Sinha R
J Maxillofac Oral Surg; 2015 Mar; 14(Suppl 1):138-44. PubMed ID: 25838687
[TBL] [Abstract][Full Text] [Related]
18. The effect of Bortezomib and Rapamycin on Telomerase Activity in Mantle Cell Lymphoma.
Uziel O; Cohen O; Beery E; Nordenberg J; Lahav M
Transl Oncol; 2014 Dec; 7(6):741-51. PubMed ID: 25500084
[TBL] [Abstract][Full Text] [Related]
19. Nanopharmacology in translational hematology and oncology.
Tomuleasa C; Braicu C; Irimie A; Craciun L; Berindan-Neagoe I
Int J Nanomedicine; 2014; 9():3465-79. PubMed ID: 25092977
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
